Compare ConocoPhillips (COP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs TG Therapeutics Inc — how do they compare? ConocoPhillips trades at $125.69 (market cap $151.27B), while TG Therapeutics Inc trades at $49.91 (market cap $7.64B). The key difference: ConocoPhillips is far larger — about 19.8× TG Therapeutics Inc's market cap, and ConocoPhillips pays a 2.67% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| COP | TGTX | |
|---|---|---|
Market Cap | $151.27B | $7.64B |
Sector | Energy | Health |
52-Week High | $133.80 | $59.06 |
52-Week Low | $85.66 | $26.94 |
Enterprise Value | $166.87B | $7.84B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $125.75, up 2.21% on the day, with a bullish technical signal and strong Q2 2026 earnings beats. The stock shows robust fundamentals with a P/E of 16.66, ROE of 14.14%, and positive free cash flow trends. Recent news highlights CEO succession and operational strength, with analyst consensus strongly favoring a buy rating.
Outlook remains positive driven by high cash flow generation and favorable oil price trends, though risks include commodity price volatility and execution of major projects. The consensus price target of $150 suggests significant upside potential from current levels.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
